Q3 revenue fell 27% year-over-year but doubled sequentially, with international sales leading and early signs of recovery. Operating loss widened, but new orders and a USPH-compliant product launch support optimism for key markets.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.